Navigation Links
TPI Receives GMP Certification for JCM Facility

CHENGDU, China, Jan. 18, 2012 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI, or the "Company"), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced the Company has received the Good Manufacturing Practice (GMP) certification for its 250-ton Jiangchuan Macrolide Facility (JCM) designated as "CHUAN M0799" valid through the period of December 31, 2011 until December 31, 2015.

Detailed information of the GMP certification for JCM facility can also be found in the official site of Sichuan Food and Drug Administration ( (Chinese version)).

About TPI

Headquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, mTCM, branded generics and API. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit:

About GMP

Good manufacturing practice (GMP) are a set of comprehensive quality management system required for pharmaceutical manufacturing covering the manufacture and testing of pharmaceuticals including APIs, diagnostics, foods, pharmaceutical products, and medical devices. GMPs are guidelines that outline the aspects of production that ensure the quality of a product.

GMP certification is conducted based on several underlying basic principles: 1) Clearly defined manufacturing processes that are controlled with critical processes validated to ensure consistency and compliance with specifications during the production; 2) Good Documentation Practices; 3) Operators are trained to carry out and document procedures; 4) Records are made, manually or by instruments, during manufacture that demonstrate that all the steps required by the defined procedures and instructions were carried out and that ensure the quantity and quality of the drug; 5) Records of manufacture and distribution that trace the complete history of a batch are retained in a comprehensible and accessible form. 6) The distribution of the drugs minimizes any risk to their quality; 7) A system is available for recalling any batch of drug from sale; 8) Complaints about marketed drugs are examined, the causes of quality defects are investigated, and appropriate measures are taken with respect to the defective drugs and to prevent recurrence.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please visit:, or email
Tel: +86-28-8551-6696 (Chengdu, China)
     +86-134-3655-0011 (China)

Tianyin Pharmaceutical
23rd Floor, Unionsun Yangkuo Plaza
No. 2, Block 3, South Renmin Road
Chengdu, 610041

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
2. Life Technologies Receives AFNOR Validation for Tests Designed to Detect Listeria Contamination in Food Samples
3. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
4. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
5. BioNeutral Group Receives $400,000 in Equity Financing
6. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
7. Intimate Bridge 2 Conception, Inc. Receives $4.3M
8. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
9. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
10. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
11. Watsons Generic Yaz(R) Receives FDA Approval
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly ... technologies, services and solutions to the healthcare market. The company's primary focus is ... manufacturing, sales and marketing strategies that are necessary to help companies efficiently bring ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... 23, 2016  The Prostate Cancer Foundation (PCF) is pleased to ... faster cures for prostate cancer. Members of the Class of 2016 were selected ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
Breaking Biology News(10 mins):